Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV-1 | 22 | 2019 | 3365 | 2.94 | Why? |
| Drug Resistance, Viral | 11 | 2019 | 1083 | 2.50 | Why? |
| HIV Infections | 29 | 2019 | 11620 | 1.73 | Why? |
| Anti-HIV Agents | 10 | 2019 | 2209 | 1.65 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 3 | 2018 | 39 | 1.06 | Why? |
| Antiretroviral Therapy, Highly Active | 6 | 2017 | 952 | 0.90 | Why? |
| Vaginal Smears | 1 | 2017 | 89 | 0.65 | Why? |
| Transients and Migrants | 3 | 2019 | 1468 | 0.65 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2018 | 139 | 0.65 | Why? |
| Ethiopia | 5 | 2019 | 1222 | 0.64 | Why? |
| HIV Integrase Inhibitors | 1 | 2018 | 173 | 0.62 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.61 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2017 | 114 | 0.61 | Why? |
| Cervix Uteri | 1 | 2017 | 146 | 0.61 | Why? |
| Treatment Failure | 6 | 2019 | 2106 | 0.60 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.59 | Why? |
| Genotype | 6 | 2019 | 4697 | 0.55 | Why? |
| Pyridones | 2 | 2018 | 738 | 0.50 | Why? |
| Lamivudine | 2 | 2017 | 210 | 0.49 | Why? |
| Reverse Transcriptase Inhibitors | 3 | 2019 | 309 | 0.49 | Why? |
| Sequence Analysis, RNA | 2 | 2018 | 2290 | 0.44 | Why? |
| Mutation | 7 | 2020 | 12376 | 0.44 | Why? |
| Sweden | 7 | 2019 | 1969 | 0.42 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 3633 | 0.39 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.36 | Why? |
| Computational Biology | 3 | 2017 | 4514 | 0.35 | Why? |
| Viral Load | 8 | 2018 | 15850 | 0.33 | Why? |
| Tenofovir | 3 | 2019 | 449 | 0.31 | Why? |
| CD4-Positive T-Lymphocytes | 5 | 2018 | 4545 | 0.29 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2018 | 275 | 0.29 | Why? |
| Chiroptera | 1 | 2020 | 3530 | 0.28 | Why? |
| Selection, Genetic | 1 | 2009 | 691 | 0.28 | Why? |
| Sequence Analysis, DNA | 3 | 2018 | 2830 | 0.24 | Why? |
| Mutation, Missense | 3 | 2018 | 863 | 0.21 | Why? |
| Chemical Precipitation | 1 | 2019 | 40 | 0.20 | Why? |
| Cohort Studies | 8 | 2019 | 36005 | 0.20 | Why? |
| Centrifugation | 1 | 2019 | 42 | 0.20 | Why? |
| Zidovudine | 1 | 2019 | 63 | 0.20 | Why? |
| Proteomics | 3 | 2020 | 2481 | 0.19 | Why? |
| Deoxyadenosines | 1 | 2018 | 12 | 0.19 | Why? |
| HIV Integrase | 1 | 2019 | 67 | 0.19 | Why? |
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2018 | 21 | 0.19 | Why? |
| Homosexuality, Male | 2 | 2019 | 1158 | 0.19 | Why? |
| Adult | 27 | 2020 | 244371 | 0.19 | Why? |
| Indinavir | 1 | 1997 | 27 | 0.18 | Why? |
| HIV Reverse Transcriptase | 3 | 2018 | 104 | 0.18 | Why? |
| RNA Virus Infections | 1 | 2020 | 231 | 0.18 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.18 | Why? |
| Stavudine | 1 | 2017 | 22 | 0.18 | Why? |
| Immunologic Surveillance | 1 | 2018 | 69 | 0.18 | Why? |
| Piperazines | 2 | 2018 | 445 | 0.18 | Why? |
| CD4 Lymphocyte Count | 3 | 2018 | 1517 | 0.18 | Why? |
| RNA Helicases | 1 | 2021 | 413 | 0.17 | Why? |
| Alkynes | 1 | 2017 | 98 | 0.17 | Why? |
| Phylogeny | 6 | 2019 | 13341 | 0.17 | Why? |
| Nevirapine | 1 | 2017 | 57 | 0.17 | Why? |
| Lymphoid Tissue | 1 | 2018 | 162 | 0.17 | Why? |
| Benzoxazines | 1 | 2017 | 103 | 0.17 | Why? |
| Retreatment | 1 | 2017 | 186 | 0.17 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.16 | Why? |
| Africa South of the Sahara | 2 | 2019 | 1335 | 0.16 | Why? |
| Tanzania | 1 | 2017 | 294 | 0.16 | Why? |
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 146 | 0.16 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.16 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.16 | Why? |
| Intention to Treat Analysis | 1 | 2018 | 673 | 0.16 | Why? |
| HIV | 3 | 2018 | 1116 | 0.16 | Why? |
| Receptors, Immunologic | 2 | 2018 | 555 | 0.15 | Why? |
| Adenine | 1 | 2018 | 463 | 0.15 | Why? |
| Mutation Rate | 1 | 2018 | 382 | 0.15 | Why? |
| Random Allocation | 1 | 2018 | 773 | 0.15 | Why? |
| Whole Exome Sequencing | 1 | 2017 | 437 | 0.15 | Why? |
| Cluster Analysis | 3 | 2018 | 3001 | 0.15 | Why? |
| Lab-On-A-Chip Devices | 1 | 2019 | 411 | 0.14 | Why? |
| Receptors, CCR5 | 1 | 2017 | 186 | 0.14 | Why? |
| Methyltransferases | 1 | 2021 | 720 | 0.14 | Why? |
| Atazanavir Sulfate | 1 | 2017 | 213 | 0.14 | Why? |
| HIV Seropositivity | 1 | 2017 | 320 | 0.14 | Why? |
| Inhibitory Concentration 50 | 1 | 2018 | 907 | 0.14 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.14 | Why? |
| Genotyping Techniques | 1 | 2017 | 360 | 0.14 | Why? |
| HIV Protease Inhibitors | 1 | 1997 | 434 | 0.13 | Why? |
| Epidemiologic Methods | 1 | 2017 | 392 | 0.13 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.13 | Why? |
| Recombination, Genetic | 2 | 2018 | 1265 | 0.13 | Why? |
| DNA | 1 | 2019 | 778 | 0.13 | Why? |
| Humans | 41 | 2021 | 930598 | 0.12 | Why? |
| Metabolome | 1 | 2017 | 624 | 0.12 | Why? |
| Female | 24 | 2020 | 380317 | 0.12 | Why? |
| Male | 22 | 2020 | 367725 | 0.12 | Why? |
| Genome-Wide Association Study | 1 | 2019 | 1648 | 0.12 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.11 | Why? |
| Swine | 1 | 2020 | 3352 | 0.11 | Why? |
| Middle Aged | 18 | 2020 | 270681 | 0.11 | Why? |
| Prevalence | 5 | 2019 | 25773 | 0.10 | Why? |
| Uterine Cervical Neoplasms | 1 | 2018 | 842 | 0.10 | Why? |
| Immunologic Memory | 2 | 2020 | 3362 | 0.10 | Why? |
| Young Adult | 7 | 2019 | 93724 | 0.10 | Why? |
| Convalescence | 1 | 2020 | 2829 | 0.09 | Why? |
| Gastrointestinal Tract | 1 | 2017 | 1113 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.09 | Why? |
| Enzyme Inhibitors | 1 | 2019 | 1881 | 0.09 | Why? |
| Viral Tropism | 1 | 2017 | 1329 | 0.09 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.09 | Why? |
| Lymphocyte Activation | 1 | 2018 | 2742 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.08 | Why? |
| Cross-Sectional Studies | 4 | 2018 | 53120 | 0.08 | Why? |
| Host-Pathogen Interactions | 2 | 2017 | 11041 | 0.08 | Why? |
| Proteome | 1 | 2017 | 1812 | 0.08 | Why? |
| Epidemics | 2 | 2017 | 6407 | 0.08 | Why? |
| Amides | 1 | 2018 | 1864 | 0.08 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.08 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2017 | 1956 | 0.08 | Why? |
| Zoonoses | 1 | 2020 | 3034 | 0.08 | Why? |
| Software | 1 | 2017 | 2501 | 0.08 | Why? |
| Adolescent | 5 | 2018 | 86841 | 0.07 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.07 | Why? |
| Disease Transmission, Infectious | 2 | 2018 | 9044 | 0.07 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.07 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2018 | 5837 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2021 | 4810 | 0.06 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.06 | Why? |
| Lopinavir | 1 | 2017 | 4308 | 0.06 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.06 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.06 | Why? |
| Immunity, Humoral | 1 | 2017 | 4849 | 0.06 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.06 | Why? |
| Amino Acid Substitution | 1 | 2009 | 1706 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.05 | Why? |
| Genes, pol | 1 | 2019 | 38 | 0.05 | Why? |
| Aged | 8 | 2020 | 215776 | 0.05 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.05 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.05 | Why? |
| Virus Diseases | 1 | 2017 | 3779 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Receptors, Virus | 1 | 2017 | 5659 | 0.05 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.05 | Why? |
| Ikaros Transcription Factor | 1 | 2018 | 10 | 0.05 | Why? |
| Plasma | 1 | 2009 | 1809 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Patents as Topic | 1 | 2021 | 224 | 0.05 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 96 | 0.04 | Why? |
| Lipogenesis | 1 | 2017 | 49 | 0.04 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.04 | Why? |
| 5' Untranslated Regions | 1 | 2020 | 375 | 0.04 | Why? |
| Infant | 2 | 2018 | 30274 | 0.04 | Why? |
| CD4-CD8 Ratio | 1 | 2018 | 235 | 0.04 | Why? |
| Histocompatibility Testing | 1 | 2017 | 219 | 0.04 | Why? |
| Solubility | 1 | 2017 | 382 | 0.04 | Why? |
| Triazoles | 1 | 2021 | 440 | 0.04 | Why? |
| Forkhead Transcription Factors | 1 | 2018 | 231 | 0.04 | Why? |
| CTLA-4 Antigen | 1 | 2018 | 282 | 0.04 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.04 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.04 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.04 | Why? |
| HLA-DR Antigens | 1 | 2018 | 563 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Databases, Nucleic Acid | 1 | 2017 | 272 | 0.04 | Why? |
| Animals | 2 | 2020 | 78931 | 0.03 | Why? |
| Polymerase Chain Reaction | 1 | 2009 | 6740 | 0.03 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.03 | Why? |
| RNA Viruses | 1 | 2020 | 824 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.03 | Why? |
| Base Sequence | 1 | 2020 | 3581 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2018 | 11559 | 0.03 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.03 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.03 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.03 | Why? |
| Open Reading Frames | 1 | 2017 | 1898 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2018 | 88759 | 0.03 | Why? |
| Signal Transduction | 2 | 2017 | 7207 | 0.03 | Why? |
| Viral Proteins | 2 | 2020 | 7370 | 0.03 | Why? |
| Immunoglobulin gamma-Chains | 1 | 1988 | 2 | 0.02 | Why? |
| Sex Characteristics | 1 | 2017 | 1120 | 0.02 | Why? |
| Europe | 2 | 2017 | 12702 | 0.02 | Why? |
| Membrane Glycoproteins | 1 | 2018 | 2273 | 0.02 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.02 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.02 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.02 | Why? |
| Child | 1 | 2017 | 70012 | 0.02 | Why? |
| Immunoglobulin Heavy Chains | 1 | 1988 | 222 | 0.02 | Why? |
| Interferon-alpha | 1 | 1995 | 1442 | 0.02 | Why? |
| Models, Molecular | 1 | 2020 | 7616 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2019 | 3388 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Hepatitis C | 1 | 1995 | 1514 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.02 | Why? |
| Ritonavir | 1 | 2018 | 4212 | 0.02 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 533 | 0.01 | Why? |
| Models, Statistical | 1 | 2019 | 5312 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.01 | Why? |
| Alanine | 1 | 2018 | 5687 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Antigens, Viral | 1 | 2017 | 6298 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Genome, Viral | 1 | 2019 | 13157 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Brain Diseases | 1 | 1988 | 1463 | 0.01 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Antibodies, Viral | 2 | 2020 | 51949 | 0.01 | Why? |
| Risk Factors | 1 | 2019 | 71621 | 0.01 | Why? |
| Alanine Transaminase | 1 | 1995 | 1329 | 0.01 | Why? |
| Recombinant Proteins | 1 | 1995 | 3786 | 0.00 | Why? |
| Liver | 1 | 1995 | 4007 | 0.00 | Why? |
| Chronic Disease | 1 | 1995 | 5139 | 0.00 | Why? |
Sönnerborg's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(221)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(100)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_